Login
$IOVA
$7.50 -$0.05 (0.66%) After hours

$IOVA 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Other Events

Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Privat...

05 Nov 2026 8-K: Results of Operations and Financial Condition

Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year,

29 Oct 2026 8-K: Other Events

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC)

05 Oct 2026 8-K: Other Events

1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview October 2026 1

29 Sep 2026 8-K: Other Events

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million

06 Aug 2026 8-K: Other Events

1 © 2026, Iovance Biotherapeutics, Inc. Corporate Overview August 2026 1

06 Aug 2026 8-K: Results of Operations and Financial Condition

U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year

02 Jul 2026 8-K: Other Events

1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview June 2026 1

10 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

First T cell therapy for a solid tumor cancer and first treatment option approved

07 May 2026 8-K: Results of Operations and Financial Condition

1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth

20 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

24 Feb 2026 8-K: Results of Operations and Financial Condition; Other Events

SAN CARLOS, Calif., February 24, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies fo...

09 Jan 2026 8-K: Other Events

1 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. Corporate Overview January 2026 1

06 Nov 2025 8-K: Results of Operations and Financial Condition

Gross Margin Increased to 43% on Improved Execution and Operational Efficiency

29 Aug 2025 8-K: Other Events

1 © 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. Corporate Overview August 2025 1

22 Aug 2025 8-K: Entry into a Material Definitive Agreement

Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”),...

19 Aug 2025 8-K: Other Events

First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy

07 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

FY25 Total Product Revenue Guidance of $250M-$300M Reiterated

15 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

SAN CARLOS, Calif., July 15, 2025 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for pa...

03 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support